VA Class: OT101
Chemical Name: ± - 9 - Fluoro - 2,3 - dihydro - 3 - methyl - 10 - (4 - methyl - 1 - piperazinyl) - 7 - oxo - 7H - pyrido[1,2,3 - de] - 1,4 - benzoxaz ine-6-carboxylicacid
Molecular Formula: C18H20FN3O4
CAS Number: 82419-36-1
Brands: Floxin Otic, Ocuflox
Uses for Ofloxacin
Bacterial Ophthalmic Infections
Treatment of conjunctivitis caused by susceptible Staphylococcus aureus, S. epidermidis, Streptococcus pneumoniae, Haemophilus influenzae, Enterobacter cloacae, Proteus mirabilis, or Pseudomonas aeruginosa.1
Role of topical fluoroquinolones in management of uncomplicated bacterial conjunctivitis not fully elucidated; some clinicians suggest that the drugs be reserved principally for severe bacterial conjunctivitis because of potential development of quinolone resistance, and possibly, cost considerations.7 80 83
Treatment of keratitis (corneal ulcers) caused by susceptible S. aureus, S. epidermidis, S. pneumoniae, Propionibacterium acnes, Ps. aeruginosa, or Serratia marcescens (designated an orphan drug by FDA for this use).1 11 91 93 94 95
Some clinicians suggest that single-agent topical fluoroquinolone therapy be considered for initial treatment in patients with equivocal gram stain results on diagnostic corneal smear, presence of >1 organism, contact lens associated keratitis (suspected to be caused by gram-negative bacteria), or in those settings where culture and susceptibility tests are impossible or impractical.91
Bacterial Otic Infections
Treatment of acute otitis media caused by susceptible S. aureus, S. pneumoniae, H. influenzae, Moraxella catarrhalis, or Ps. aeruginosa.105
Ofloxacin Dosage and Administration
Apply topically to the eye as an ophthalmic solution.1
For treatment of bacterial keratitis, administer around the clock for first 2 days of therapy.1
Instill into ear as otic solution.105
Prior to administration, warm container in hand for 1–2 minutes before use to avoid dizziness associated with instillation of cold solution into ear canal.105
Patient should lie with the affected ear upward and the otic preparation should be instilled into the ear canal; maintain position for 5 minutes to facilitate penetration of drops into ear canal.105 Repeat for opposite ear if necessary.105
To administer for treatment of otitis media in pediatric patients with tympanostomy tubes, instill drops while the affected ear is upward.105 Pump tragus 4 times by pushing inward to facilitate penetration of drops into middle ear; maintain position 5 minutes.105 Repeat for opposite ear if necessary.105
Bacterial Ophthalmic Infections
Children≥1 year of age: 1 or 2 drops of 0.3% solution into affected eye(s) every 2–4 hours while awake for 2 days, then 1–2 drops 4 times daily for up to 5 more days.1
Children≥1 year of age: 1 or 2 drops of 0.3% solution into affected eye(s) every 30 minutes while awake and then 4 and 6 hours after retiring, for 2 days.1 Beginning on the third day, instill 1 or 2 drops into affected eye(s) every hour while awake for up to an additional 4–6 days.1 Afterward, may instill 1 or 2 drops into affected eye(s) 4 times daily for additional 3 days or until clinical cure achieved.1
Bacterial Otic Infections
Children 6 months to 13 years of age: 5 drops of 0.3% solution into canal of affected ear(s) once daily for 7 days.a
Children ≥13 years of age: 10 drops of 0.3% solution into canal of affected ear(s) once daily for 7 days.a
Acute Otitis MediaOtic
Children 1–12 years of age with tympanostomy tubes: 5 drops of 0.3% solution into canal of affected ear(s) twice daily for 10 days.105
Chronic Suppurative Otitis MediaOtic
Children ≥12 years of age with perforated tympanic membranes: 10 drops of 0.3% solution into canal of affected ear(s) twice daily for 14 days.105
Bacterial Ophthalmic Infections
1 or 2 drops of 0.3% solution into affected eye(s) every 2–4 hours while awake for 2 days, then 1–2 drops 4 times daily for up to 5 more days.1
1 or 2 drops of a 0.3% solution into affected eye(s) every 30 minutes while awake and then 4 and 6 hours after retiring, for 2 days.1 Beginning on third day, instill 1 or 2 drops into affected eye(s) every hour while awake for up to an additional 4–6 days.1 Afterward, may instill 1 or 2 drops into affected eye(s) 4 times daily for additional 3 days or until clinical cure achieved.1
Bacterial Otic Infections
10 drops of 0.3% solution into canal of affected ear(s) once daily for 7 days.a
Chronic Suppurative Otitis MediaOtic
10 drops of 0.3% solution into canal of affected ear(s) twice daily for 14 days in patients with perforated tympanic membranes.105
Cautions for Ofloxacin
In patients with ophthalmic infections, careful monitoring, including slit-lamp biomicroscopy and fluorescein staining when appropriate, may be necessary in some patients.1
If otic infection is not improved after 1 week of treatment, obtain cultures to guide treatment.105 If otorrhea persists after completion of therapy, or if ≥2 episodes of otorrhea occur within 6 months, further evaluate to exclude underlying condition (e.g., cholesteatoma, foreign body, tumor).105
Ophthalmic solution: safety and efficacy not established in children <1 year of age.1
Otic solution: safety and efficacy for treatment of otitis externa with intact typanic membrane not established in children <6 months of age.a Safety and efficacy for treatment of acute otitis media with tympanostomy tubes not established in children <1 year of age.105 Safety and efficacy for treatment of chronic suppurative otitis media with perforated tympanic membranes not established in children <12 years of age.105 Although no data are available in patients <6 months of age, there are no known safety concerns or differences in disease process to preclude use in this population.a
No changes in hearing function observed on audiometric evaluation in a limited number of children treated with otic solution.105
No substantial differences in safety or efficacy of ophthalmic solution relative to younger adults.1
Common Adverse Effects
Ophthalmic solution: extent of ocular or systemic absorption after topical application to the eye not fully elucidated, but mean serum ofloxacin concentrations after 10 days of topical ophthalmic dosing are >1000 times lower than those reported with standard oral doses.1 19 70
Otic solution: extent of otic or systemic absorption after topical application to the ear not fully elucidated, but serum ofloxacin concentrations achieved after such application are minimal relative to those produced by usual oral or parenteral doses.105 108
Excreted principally in urine unchanged.1
25°C (may be exposed to 15–30°C).a
Actions and Spectrum
Active in vitro against most gram-negative aerobic bacteria, including Enterobacteriaceae and Ps. aeruginosa.1 3 8 21 22 25 26 27 44 64 65 66 67 68 72 84 85 Active in vitro against many gram-positive aerobic bacteria, including penicillinase-producing, nonpenicillinase-producing, and some oxacillin-resistant staphylococci (previously known as methicillin-resistant staphylococci).1 3 8 21 22 25 26 27 44 64 65 66 67 68 72 84 85 Less active against gram-positive than -negative bacteria.3 8 25 26
Advice to Patients
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.
* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name
Ocuflox (with benzalkonium chloride)
Ofloxacin Ophthalmic Solution
Bausch & Lomb
Floxin Otic (with benzalkonium chloride)
AHFS DI Essentials. © Copyright 2017, Selected Revisions June 1, 2006. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.
1. Allergan. Ocuflox (ofloxacin ophthalmic solution) 0.3% sterile prescribing information. Irvine, CA; 2000 Nov.
2. Hooper DC, Wolfson JS. The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans. Antimicrob Agents Chemother. 1985; 28:716-21. [IDIS 208219] [PubMed 2936302]
3. Wolfson JS, Hooper DC. The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob Agents Chemother. 1985; 28:581-6. [IDIS 207617] [PubMed 3000292]
4. Felmingham D, Foxall P, O’Hare MD et al. Resistance studies with ofloxacin. J Antimicrob Chemother. 1988; 22(Suppl C):27-34. [PubMed 3182460]
5. Neu HC. Chemical evolution of the fluoroquinolone antimicrobial agents. Am J Med. 1989; 87(Suppl 6C):2-9S. [IDIS 262515] [PubMed 2500854]
6. McDonnell PJ, Green WR. Conjunctivitis. In: Mandell GL, Douglas RG Jr, Bennett JE, eds. Principles and practices of infectious diseases. 3rd ed. New York: Churchill Livingstone; 1990:975-82.
7. Yolton DP. New antibacterial drugs for topical ophthalmic use. Optom Clin. 1992; 2:59-72. [PubMed 1286241]
8. Todd PA, Faulds D. Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology and therapeutic use. Drugs. 1991; 42:825-76. [PubMed 1723377]
9. Bearden DT, Danziger LH. Mechanism of Action of and resistance to quinolones. Pharmacotherapy. 2001; 21:224S-32S [IDIS 472236] [PubMed 11642689]
11. Food and Drug Administration. Orphan designations pursuant to section 526 of the Federal Food and Cosmetic Act as amended by the Orphan Drug Act (P.L. 97-414), to June 28, 1996. Rockville, MD; 1996 Jul.
14. Chantot JF, Bryskier A. Antibacterial activity of ofloxacin and other 4-quinolone derivatives: in-vitro and in-vivo comparison. J Antimicrob Chemother. 1985; 16:475-84. [PubMed 3864775]
15. Alcon Laboratories. Product monograph. Ciloxan (ciprofloxacin HCl) 0.3% as base sterile ophthalmic solution. Fort Worth, TX: 1991 Apr.
16. Alcon Laboratories. Ciloxan (ciprofloxacin HCl) 0.3% as base sterile ophthalmic solution prescribing information. In: Physicians’ desk reference. 46th ed. Montvale, NJ: Medical Economics Company Inc; 1992:211-3.
17. Nelson JD, Silverman V, Lima PH et al. Corneal epithelial wound healing: a tissue culture assay on the effect of antibiotics. Curr Eye Res. 1990; 9:277-85. [PubMed 2347205]
18. Kawasaki K, Mochizuki K, Torisaki M et al. Electroretinographical changes due to antimicrobials. Lens Eye Toxic Res. 1990; 7:693-704. [PubMed 2100188]
19. Borrmann L, Tang-Liu DDS, Kann J et al. Ofloxacin in human serum, urine and tear film after topical application. Cornea. 1992; 11:226-30. [PubMed 1587130]
20. Cutarelli PE, Lass JH, Lazarus HM et al. Topical fluoroquinolones: antimicrobial activity and in vitro corneal epithelial toxicity. Curr Eye Res. 1991; 10:557-63. [PubMed 1893771]
21. Hayakawa I, Atarashi S, Yokohama S et al. Synthesis and antibacterial activities of optically active ofloxacin. Antimicrob Agents Chemother. 1986; 20:163-4.
22. Inagaki Y, Horiuchi S, Une T et al. In-vitro activity of DR-3355, an optically active isomer of ofloxacin, against bacterial pathogens associated with travellers’ diarrhoea. J Antimicrob Chemother. 1989; 24:547-9. [PubMed 2613604]
23. McNeil Pharmaceutical. Floxin I.V. (ofloxacin injection) for intravenous infusion. Springhouse, PA; 1992 Apr.
24. McNeil Pharmaceutical, Springhouse, PA: personal communication.
25. Smythe MA, Rybak MJ. Ofloxacin: a review. DICP. 1989; 23:839-46. [IDIS 260674] [PubMed 2688325]
26. Paton JH, Reeves DS. Fluoroquinolone antibiotics: microbiology, pharmacokinetics and clinical uses. Drugs. 1988; 36:193-228. [IDIS 245416] [PubMed 3053126]
27. Monk JP, Campoli-Richards DM. Ofloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1987; 33:346-91. [IDIS 236762] [PubMed 3297617]
28. Une T, Fujimoto T, Sato K et al. In vitro activity of DR-3355, an optically active ofloxacin. Antimicrob Agents Chemother. 1988; 32:1336-40. [IDIS 248086] [PubMed 3195996]
29. Crumplin GC. Aspects of chemistry in the development of the 4-quinolone antibacterial agents. Rev Infect Dis. 1988; 10(Suppl 1):S2-9. [IDIS 311592] [PubMed 3279494]
30. Hoshino K, Sato K, Akahane K et al. Significance of the methyl group on the oxazine ring of ofloxacin derivatives in the inhibition of bacterial and mammalian type II topoisomerases. Antimicrob Agents Chemother. 1991; 35:309-12. [IDIS 278271] [PubMed 1850968]
31. Pascual A, Garcia I, Perea EJ. Uptake and intracellular activity of an optically active ofloxacin isomer in human neutrophils and tissue culture cells. Antimicrob Agents Chemother. 1990; 34:277-80. [PubMed 2327777]
32. Minguez F, Gomez-Luz ML, Muro A et al. Comparative study of the postantibiotic effect of cefotaxime, amoxicillin, ofloxacin, and pefloxacin. Rev Infect Dis. 1989; 11(Suppl 5):S955-7.
33. Sato K, Hoshino K, Une T et al. Inhibitory effects of ofloxacin on DNA gyrase of Escherichia coli and topoisomerase II of bovine calf thymus. Rev Infect Dis. 1989; 11(Suppl 5):S915-6.
34. Fung-Tomc J, Desiderio JV, Tsai YH et al. In vitro and in vivo antibacterial activities of BMY 40062, a new fluoronaphthyridone. Antimicrob Agents Chemother. 1989; 33:906-14. [IDIS 255721] [PubMed 2764541]
35. Fuchs PC. In vitro antimicrobial activity and susceptibility testing of ofloxacin. Am J Med. 1989; 87(Suppl 6C):10-3S.
36. Nishino T, Tanaka M, Ohtsuki M. Effect of ofloxacin on the ultrastructure of Escherichia coli and Pseudomonas aeruginosa in the logarithmic and stationary phases of growth. Rev Infect Dis. 1989; 11(Suppl 5):S914-5.
37. Imamura M, Shibamura S, Hayakawa I et al. Inhibition of DNA gyrase by optically active ofloxacin. Antimicrob Agents Chemother. 1987; 31:325-7. [PubMed 3032098]
38. Lode H, Hoffken G, Olschewski P et al. Pharmacokinetics of ofloxacin after parenteral and oral administration. Antimicrob Agents Chemother. 1987; 31:1338-42. [IDIS 236950] [PubMed 3479046]
39. Jensen T, Pedersen SS, Nielsen CH et al. The efficacy and safety of ciprofloxacin and ofloxacin in chronic Pseudomonas aeruginosa infection in cystic fibrosis. J Antimicrob Chemother. 1987; 20:585-94. [PubMed 3479420]
40. Nix DE, Schentag JJ. The quinolones: an overview and comparative appraisal of their pharmacokinetics and pharmacodynamics. J Clin Pharmacol. 1988; 28:169-78. [IDIS 241560] [PubMed 3283180]
41. Wise R, Lockley MR. The pharmacokinetics of ofloxacin and a review of its tissue penetration. J Antimicrob Chemother. 1988; 22(Suppl C):59-64. [PubMed 3182463]
42. Wolfson JS, Hooper DC. Comparative pharmacokinetics of ofloxacin and ciprofloxacin. Am J Med. 1989; 87(Suppl 6C):31-6S.
43. Outman WR, Nightingale CH. Metabolism and the fluoroquinolones. Am J Med. 1989; 87(Suppl 6C):37-42S.
44. Drew RH, Gallis HA. Ofloxacin: its pharmacology, pharmacokinetics, and potential for clinical application. Pharmacotherapy. 1988; 8:35-46. [IDIS 389860] [PubMed 3287354]
46. Hooper DC, Wolfson JS. Bacterial resistance to the quinolone antimicrobial agents. Am J Med. 1989; 87(Suppl 6C):17-23S.
47. Neu HC. Bacterial resistance to fluoroquinolones. Rev Infect Dis. 1988; 10(Suppl 1):S57-63. [IDIS 311595] [PubMed 3279500]
48. Davis GJ, McKenzie BE. Toxicologic evaluation of ofloxacin. Am J Med. 1989; 87(Suppl 6C):43-6S.
49. Mayer DG. Overview of toxicological studies. Drugs. 1987; 34(Suppl 1):150-3. [PubMed 3325258]
50. Takayama S, Watanabe T, Akiyama Y et al. Reproductive toxicity of ofloxacin. Arzneimittelforschung. 1986; 36:1244-8. [PubMed 3465327]
51. Kato M, Onodera T. Morphological investigation of cavity formation in articular cartilage induced by ofloxacin in rats. Fund Appl Toxicol. 1988; 11:110-9.
52. McQueen CA, Williams GM. Effects of quinolone antibiotics in tests for genotoxicity. Am J Med. 1987; 82(Suppl 4A):94-6.
53. Stahlmann R. Safety profile of the quinolones. J Antimicrob Chemother. 1990; 26(Suppl D):31-44. [PubMed 2286589]
54. Christ W, Lehnert T, Ulbrich B. Specific toxicologic aspects of the quinolones. Rev Infect Dis. 1988; 10(Suppl 1):S141-6. [IDIS 311600] [PubMed 3279489]
55. Kohler RB, Arkins N, Tack KJ. Accidental overdose of intravenous ofloxacin with benign outcome. Antimicrob Agents Chemother. 1991; 35:1239-40. [IDIS 283450] [PubMed 1929271]
56. Koppel C, Hopfe T, Menzel J. Central anticholinergic syndrome after ofloxacin overdose and therapeutic doses of diphenhydramine and chlormezanone. J Toxicol Clin Toxicol. 1990; 28:249-53. [IDIS 272236] [PubMed 2398523]
57. Bron A, Talon D, Estavoyer JM et al. Ocular distribution of the new quinolones. Rev Infect Dis. 1989; 11(Suppl 5):S1206-7.
58. Giamarellou H, Kolokythas E, Petrikkos G et al. Pharmacokinetics of three newer quinolones in pregnant and lactating women. Am J Med. 1989; 87(Suppl 5A):49-51S.
59. Sorgel F, Jaehde U, Naber K et al. Pharmacokinetic disposition of quinolones in human body fluids and tissues. Clin Pharmacokinet. 1989; 16(Suppl 1):5-24. [IDIS 253937] [PubMed 2653696]
60. Okezaki E, Terasaki T, Nakamura M et al. Serum protein binding of lomefloxacin, a new antimicrobial agent, and its related quinolones. J Pharm Sci. 1989; 78:504-7. [IDIS 255802] [PubMed 2760827]
61. Muth P, Marx T, Sorgel F. Penetration of ofloxacin into maternal milk. Rev Infect Dis. 1989; 11(Suppl 5):S1079-80. [IDIS 307980] [PubMed 2549606]
64. Neu HC. Microbiologic aspects of fluoroquinolones. Am J Ophthalmol. 1991; 112:15-24S. [IDIS 284787] [PubMed 1882916]
65. Osato MS, Jensen HG, Trousdale MD et al. The comparative in vitro activity of ofloxacin and selected ophthalmic antimicrobial agents against ocular bacterial isolates. Am J Ophthalmol. 1989; 108:380-6. [IDIS 268840] [PubMed 2519514]
66. Neu HC, Kumada T, Chin NX et al. The post-antimicrobial suppressive effect of quinolone agents. Drugs Exp Clin Res. 1987; 13:63-7. [PubMed 3107958]
67. Minguez F, Ramos C, Barrientos S et al. Postantibiotic effect of ciprofloxacin compared with that of five other quinolones. Chemotherapy. 1991; 37:420- 5. [IDIS 293433] [PubMed 1760941]
68. Howard BMA, Pinney RJ, Smith JT. Post-antibiotic effects of ofloxacin on Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus, and Streptococcus pyogenes. Chemotherapy. 1993; 39: 265-71.
69. Bron AJ, Leber G, Rizk SNM et al. Ofloxacin compared with chloramphenicol in the management of external ocular infection. Br J Ophthalmol. 1991; 75:675-9. [PubMed 1751464]
70. Bormann L, Tang-Liu D, Kann J et al. Tear levels and systemic absorption of ofloxacin eyedrops in humans. Invest Ophthalmol Vis Sci. 1989; 30:247.
71. Gritz DC, McDonnell PJ, Lee TY et al. Topical ofloxacin in the treatment of pseudomonas keratitis in a rabbit model. Cornea. 1992; 11:143-7. [PubMed 1582217]
72. Richman J, Zolezio H, Tang-Liu D. Comparison of ofloxacin, gentamicin, and tobramycin concentrations in tears and in vitro MICs for 90% of test organisms. Antimicrob Agents Chemother. 1990; 34:1602-4. [PubMed 2221871]
73. Lesar TS, Fiscella RG. Antimicrobial drug delivery to the eye. Drug Intell Clin Pharm. 1985; 19:642-54. [IDIS 205138] [PubMed 3899562]
75. Fisch A, Lafaix C, Salvanet A et al. Ofloxacin in human aqueous humour and lens. Antimicrob Agents Chemother. 1987; 20:453-4.
76. Giamarellou H, Kanellas D, Kavouklis E et al. Comparative pharmacokinetics of ciprofloxacin, ofloxacin and pefloxacin in human aqueous humour. Eur J Clin Microbiol Infect Dis. 1993; 12:293-7. [PubMed 8513819]
77. Barza M. Use of quinolones for treatment of ear and eye infections. Eur J Clin Microbiol Infect Dis. 1991; 10:296-303. [PubMed 1864290]
78. Bron A, Talon D, Delbosc B et al. La pénétration intracamérulaire de l’ofloxacine chez l’homme. (French; with English abstract.) J Fr Ophtalmol. 1987; 10:443-6.
79. El Baba FZ, Trousdale MD, Gauderman WJ et al. Intravitreal penetration of oral ciprofloxacin in humans. Ophthalmology. 1992; 99:483-6. [PubMed 1584563]
80. Gwon A for the Ofloxacin Study Group II. Ofloxacin vs tobramycin for the treatment of external ocular infection. Arch Ophthalmol. 1992; 110:1234-7. [IDIS 301536] [PubMed 1520109]
81. Gwon A for the Ofloxacin Study Group. Topical ofloxacin compared with gentamicin in the treatment of external ocular infection. Br J Ophthalmol. 1992; 76:714-8. [PubMed 1486071]
82. Limberg MB. A review of bacterial keratitis and bacterial conjunctivitis. Am J Ophthalmol. 1991; 112:2-9S.
83. Reviewers’ comments (personal observations) ciprofloxacin ophthalmic solution.
84. Fu KP, Lafredo SC, Foleno B et al. In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin. Antimicrob Agents Chemother. 1992; 36:860-6. [PubMed 1503449]
85. Ortho-McNeil Pharmaceutical. Floxin (ofloxacin) tablets prescribing information. Raritan, NJ; 2000 Feb.
86. Flor S. Pharmacokinetics of ofloxacin. Am J Med. 1989; 87(Suppl 6C): 24-30S. [IDIS 262518] [PubMed 2603892]
87. Tang-Liu DDS, Schwob DL, Usansky JI et al. Comparative tear concentrations over time of ofloxacin and tobramycin in human eyes. Clin Pharmacol Ther. 1994; 55:284-92. [IDIS 328486] [PubMed 8143394]
88. Reviewers’ comments (personal observations).
89. Allergan, Irvine, CA: Personal communication.
90. Matsumoto SS, Stern ME, Oda RM et al. Effect of ofloxacin on corneal epithelial wound healing evaluated by in vitro and in vivo methods. Drug Invest. 1993; 6:96-103.
91. O’Brien TP, Maguire MG, Fink NE et al et al. Efficacy of ofloxacin vs cefazolin and tobramycin in the therapy for bacterial keratitis: report from the Bacterial Keratitis Study Research Group. Arch Ophthalmol. 1995; 113:1257-65. [IDIS 354963] [PubMed 7575256]
92. Donnenfeld ED, Perry HD, Snyder RW et al. Intracorneal, aqueous humor, and vitreous humor penetration of ofloxacin. Proceedings from the Ocular Microbiology and Immunology Group, 28th Annual Meeting, Oct 29, 1994. Abstract No. 40.
93. Srinivasan M, Stoecker JF, Sundar K et al. Successful treatment of bacterial corneal ulceration with 0.3% ofloxacin ophthalmic solution. Invest Ophthalmol Vis Sci. 1995; 36:746.
94. Sheppard JD, Srinivasan M, Stoecker JF et al. Clinical efficacy of 0.3% ofloxacin solution in patients with bacterial keratitis caused by Staphylococcus species or Pseudomonas aeruginosa. Invest Ophthalmol Vis Sci. 1995; 36:743.
95. Allergan, Irvine, CA: Personal communication.
97. Alcon Laboratories. Ciloxan product monograph. Ciloxan (ciprofloxacin HCl) 0.3% as base sterile ophthalmic solution. Fort Worth, TX: 1991 Apr.
98. Anon. Ophthalmic ciprofloxacin. Med Lett Drugs Ther. 1991; 33:52-3. [PubMed 2030657]
99. Leibowitz HM. Clinical evaluation of ciprofloxacin 0.3% ophthalmic solution for treatment of bacterial keratitis. Am J Ophthalmol. 1991; 112:34-47S. [IDIS 288796] [PubMed 1882919]
100. Bower KS, Kowalski RP, Gordon YJ. Fluoroquinolones in the treatment of bacterial keratitis. Am J Ophthalmol. 1996; 121:712-5. [IDIS 369221] [PubMed 8644818]
101. McLeod SD, DeBacker CM, Viana MA. Differential care of corneal ulcers in the community based on apparent severity. Ophthalmology. 1996; 103:479-84. [PubMed 8600426]
102. McDonnell PJ. Empirical or culture-guided therapy for microbial keratitis? A plea for data. Arch Ophthalmol. 1996; 114:84-7. [PubMed 8540856]
103. Baum J. Infections of the eye. Clin Infect Dis. 1995; 21:479-88. [IDIS 354808] [PubMed 8527532]
104. Diamond JP, White L, Leeming JP et al. Topical 0.3% ciprofloxacin, norfloxacin, and ofloxacin in the treatment of bacterial keratitis: a new method for comparative evaluation of ocular drug penetration. Br J Ophthalmol. 1995; 79:606-609. [PubMed 7626579]
105. Daiichi Pharmaceutical Corp. Floxin (ofloxacin) otic solution 0.3% prescribing information. Montvale, NJ; 1999 Oct 15.
106. Jones RN, Milazzo J, Seidlin M. Ofloxacin otic solution for treatment of otitis externa in children and adults. Arch Otolaryngol Head Neck Surg. 1997; 123:1193-1200. [PubMed 9366699]
107. Agro AS, Garner ET, Wright JW III et al. Clinical trial of ototopical ofloxacin for treatment of chronic suppurative otitis media. Clin Ther. 1998; 20:744-59. [IDIS 412469] [PubMed 9737834]
108. Daiichi Pharmaceutical Corp, Fort Lee, NJ: Personal communication.
109. Bayer Corporation. Cipro HC Otic (ciprofloxacin hydrochloride and hydrocortisone) otic suspension prescribing information (dated 1998 Mar). In: Physicians’ desk reference. 52nd ed. Montvale, NJ: Medical Economics Company Inc; 1998(Suppl A):A9.
110. Johnson MP, Ramphal R. Malignant external otitis: report on therapy with ceftazidime and review of therapy and prognosis. Clin Infect Dis. 1990; 12:173-80.
111. Hern JD, Ghufoor K, Jayaraj SM et al. ENT manifestations of Pseudomonas aeruginosa infection in HIV and AIDS. Int J Clin Pract. 1998; 52:141-4. [IDIS 404400] [PubMed 9684426]
112. Indudharan R, Haq JA, Aiyar S. Antibiotics in chronic suppurative otitis media: a bacteriologic study. Ann Otol Rhinol Laryngol. 1999; 108:440-5. [PubMed 10335703]
113. Bluestone CD, Klein JO. Chronic suppurative otitis media. Pediatr Rev. 1999; 20:277-9. [PubMed 10429148]
114. Bluestone CD. Ear and mastoid infections. In: Gorbach SL, Bartlett JG, Blacklow NR, eds. Infectious Diseases. Philadelphia, PA: WB Saunders; 1998:530-9.
115. Goldblatt EL, Dohar J, Nozza RJ et al. Topical ofloxacin versus systemic amoxicillin/clavulanate in purulent otorrhea in children with tympanostomy tubes. Int J Pediatr Otorhinolaryngology. 1998:91-101.
a. Daiichi Pharmaceutical Corp. Floxin (ofloxacin) otic solution 0.3% prescribing information. Montvale, NJ; 2004 May.
More about ofloxacin ophthalmic
- Other brands: Ocuflox